Local News: Coral Gables, FL 

 | 

Sign Up

 | 

Sign In

Advertisment

Abbott Laboratories

Abbott Laboratories News Editors

RoboBlogger

I edit this news page on Topix when no humans are available to help.

People just like you make Abbott Laboratories News on Topix better every day. If you're interested in becoming an editor, apply today!

Edits History | Editor Blog

RSS icon mobile icon

Abbott Laboratories News

News on Abbott Laboratories continually updated from thousands of sources around the net.

23 hrs ago | MediLexicon

Abbott To Develop New Heart Failure Test On ARCHITECT Immunochemistry Diagnostics Platform

Abbott and BG Medicine, Inc. announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure.

Comment?

Related Topix: Biotech, Medicare, Health

Sat Nov 21, 2009

The Straits Times

FDA review diet drug risks

US REGULATORS are reviewing preliminary data suggesting patients taking Abbott Laboratories Inc's weight loss drug Meridia may have a higher risk of cardiovascular problems, the Food and Drug Administration said on Friday.

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Meridia, Sibutramine (generic), Medication

Fri Nov 20, 2009

Texas Lawyer

Opinion: Venue Shopping in Patent Cases Must Stop

There is nearly universal agreement that reform of the U.S. patent system is urgently needed.

Comment?

Related Topix: Inventions, Science / Technology, Microsoft, Software, Marshall, TX, Biotech, Opinion

Thu Nov 19, 2009

FOX 4 Now - WFTX Home

How older workers can lighten the load

Annis Fuller thought she had everything in place to retire this past June. But when the Abbott Laboratories accountant and her husband, who manages construction projects for the company, met with their financial planner last December, the news wasn't good.

Comment?

Related Topix: Biotech, Pension, Personal Finance

Wed Nov 18, 2009

News Chief

Sector Snap: UBS upbeat on medical tech stocks

A UBS analyst said Wednesday that medical technology stocks are trading at attractive prices, and raised his ratings or price targets on nine of them.

Comment?

Related Topix: Medicine, Boston Scientific, Medical Equipment, Healthcare Industry, Zimmer Holdings, Natick, MA, Biotech

WMAQ-TV

Clinton and Bush to Give Joint Talk in Chicago

Former presidents Bill Clinton and George W. Bush are used to playing for different teams.

Comment?

Related Topix: Chicago Metro, Bill Clinton, George Bush, History in the News, US Politics, US News, Al Gore, Biotech, North Chicago, IL

Tue Nov 17, 2009

Pharmaceutical Online

Abbott Announces Positive Three-Year Data On Its Fully...

Abbott today announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries.

Comment?

Related Topix: Biotech

Mon Nov 16, 2009

News Sun

Firms can save by going green

Somewhere in Chicago right now, there's a salesman in a company SUV, idling the engine while he makes calls in a restaurant parking lot.

Comment?

Related Topix: Chicago Metro, Biotech

Bloomberg

Abbott's Niaspan Works Better Than Merck's Zetia in Artery Clearing Study

A finding that Merck & Co.a s cholesterol pills Vytorin and Zetia didna t reopen clogged arteries as well as Abbott Laboratories a Niaspan has set off a medical debate on heart treatment strategies.

Comment?

Related Topix: Zetia, Ezetimibe (generic), Medication, Medicine, Niacin (generic), Niaspan, Niacor, Biotech, Cholesterol, Health, Abbott Laboratories

Sat Nov 14, 2009

WebWire

PanGenetics announces acquisition by Abbott of PG110 anti-NGF antibody to treat chronic pain.

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor , today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic.

Comment?

Related Topix: Biotech, Chronic Pain, Medicine, Arthritis

Fri Nov 13, 2009

People's Daily Online

Growing Chinese economy brings opportunities for multinational companies

The growth of the Chinese economy has brought opportunities for multinational companies and has a great future, according to a senior executive from U.S. health care company Abbott Laboratories.

Comment?

Related Topix: World News, China, Asia, Biotech

American Chronicle

News and FDA Updates for Abbott

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/12/09, Abbott announced a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor , expanding the company's pain care portfolio and leveraging its expertise in biologics.

Comment?

Related Topix: Healthcare Law, Law, Food and Drug Administration, Biotech, Opinion

Thu Nov 12, 2009

Drugs.com

Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor , expanding the company's pain care portfolio and leveraging its expertise in biologics.

Comment?

Related Topix: Biotech, Chronic Pain, Medicine

Wed Nov 11, 2009

Freshnews

Arnold & Itkin Announces Lawsuits Over Defective Pain Pumps

The Houston trial law firm Arnold & Itkin LLP has filed five lawsuits against the makers of pain pumps and related medications based on claims that many of the companies' defective devices are causing irreversible shoulder damage among patients.

Comment?

Related Topix: Healthcare Law, Law, Food and Drug Administration, Medicine, Stryker, Medical Equipment, Healthcare Industry, IFlow, Biotech

Blogging Stocks

Cramer on BloggingStocks: Pelosi can't kill the health care sector

Filed under: Market matters , Abbott Laboratories , Aetna Inc , CIGNA Corp , Gilead Sciences , Stocks to Buy , Cramer on BloggingStocks TheStreet.com's Jim Cramer says the Senate is filled with more-savvy politicians, and the upside for beaten-down names is huge.

Comment?

Related Topix: Biotech, Aetna, Insurance, Cigna, Medicine, Gilead Sciences, Healthcare Industry, Financial Markets

Tue Nov 10, 2009

The Motley Fool

2 Winning Trends for 2010

He's up 1,334%! See what David's recommending that you buy NEXT! Click here now to find out! At least so far, 2009 has been a welcome relief from the pain that 2008 inflicted on most investors.

Comment?

Related Topix: Financial Markets, Biotech, Johnson and Johnson, Medicine, Healthcare Industry

Mon Nov 09, 2009

Fortune

Go the distance - Dividends for the long run

This is shaping up as the worst year for dividend cuts in three generations. Striving to conserve cash amid the most severe slump since the Depression, companies are reducing or eliminating their payouts to shareholders.

Comment?

Related Topix: Rubber-Plastics, Manufacturing, Dow Chemical, Chemicals, Biotech, Pfizer, Medicine, Healthcare Industry, Financial Markets, Verizon Communications, Telecom, IT Services

Sun Nov 08, 2009

Rocky Mount Telegram

Scam victims left to pick up pieces after losing everything

In 2001, Lillie Greene's life was turned upside down. Her son, not knowing he was diabetic, suffered an aneurysm and went into a coma for 32 days.

Comment?

Related Topix: Biotech, Abbott Laboratories, Personal Finance, Retirement, Social Security

Fri Nov 06, 2009

Chicago Tribune

Abbott under kickback probe over Depakote sales

Abbott Laboratories this morning confirmed the company's sales and marketing practices of Depakote, the widely used drug to treat bipolar disorder and epilepsy, are under federal investigation.

1 comment

Related Topix: Biotech, Medicine, Medication, Depakote, Valproic Acid (generic), Abbott Laboratories, Marketing, Bipolar Disorder, Health, Epilepsy

Thu Nov 05, 2009

Bloomberg

Abbott's $1.67 Billion Patent-Suit Loss to J&J Over Humira Upheld By Judge

Abbott Laboratories failed to convince a federal judge to throw out a record $1.67 billion verdict won by Johnson & Johnsona s Centocor unit in a suit over an arthritis drug patent.

Comment?

Related Topix: Biotech, Food, J and J Snack Foods, Abbott Laboratories, Medicine, Healthcare Industry, Arthritis, Health, Marshall, TX

Coral Gables Jobs

Also on Topix